Ticker

Fresenius Medical Care AG and Co. KGaA (NYSE: FMS - Get Free Report) and Bluejay Diagnostics (NASDAQ: BJDX - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends. Analyst Recommendations This

ACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on rapid, near-patient testing, today announced the successful enrollment of 624 patients in its ongoing SYMON-II Trial, a pivotal clinical study evaluating the Company's Symphony™ platform for interleukin-6 (IL-6) testing in critical care settings to determine patient acuity…

Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and Bluejay Diagnostics (NASDAQ: BJDX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk. Volatility and Risk Coloplast A/S has a beta

New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented. New clinical data from the SYMON-I study to evaluate IL-6 and organ dysfunction in sepsis patients to be presented.

NEWPORT BEACH, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- NorthStrive Fund II LP (“NorthStrive Fund”), a subsidiary of NorthStrive Companies Inc., today issued an open letter to the Board of Directors and shareholders of Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) recommending the Board evaluate a strategic opportunity that NorthStrive believes could significantly enhance long-term shareholder value.